Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy

Autor: Jie‑Wen Peng, Jian‑Jun Xiao, Dong‑Ying Liu, Pan Pan Liu, Gui Nan Lin, Zhong Jun Xia
Rok vydání: 2015
Předmět:
0301 basic medicine
Adult
Male
medicine.medical_specialty
Pathology
Organoplatinum Compounds
Colorectal cancer
medicine.medical_treatment
Leucovorin
Monocyte
Gastroenterology
lcsh:RC254-282
Drug Administration Schedule
Monocytes
03 medical and health sciences
0302 clinical medicine
FOLFOX
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Lymphocyte Count
Neoplasm Metastasis
Survival analysis
Aged
Inflammation
Chemotherapy
business.industry
Surrogate endpoint
Proportional hazards model
Metastatic colorectal cancer
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Survival Analysis
Oxaliplatin
030104 developmental biology
Treatment Outcome
Oncology
Fluorouracil
030220 oncology & carcinogenesis
Female
Original Article
Lymphocyte
business
Colorectal Neoplasms
medicine.drug
Zdroj: Chinese Journal of Cancer
Chinese Journal of Cancer, Vol 35, Iss 1, Pp 1-9 (2016)
ISSN: 1944-446X
Popis: Background As a surrogate marker of systemic inflammation, the lymphocyte-to-monocyte ratio (LMR) is an independent prognostic factor for various malignancies. This study investigated the prognostic significance of the pre-chemotherapy LMR in patients with previously untreated metastatic colorectal cancer (mCRC) receiving chemotherapy. Methods The present study included newly diagnosed mCRC patients treated between January 2005 and December 2013 with FOLFOX chemotherapy, specifically oxaliplatin 180 mg/m2 on day 1, with leucovorin 400 mg/m2 administered as a 2-hour infusion before the administration of 5-fluorouracil 400 mg/m2 as an intravenous bolus injection, and 5-fluorouracil 2400 mg/m2 as a 46-h infusion immediately after 5-fluorouracil bolus injection. The LMR was calculated as the absolute count of lymphocytes divided by the absolute count of monocytes. COX proportional hazards analysis was performed to evaluate the association of LMR with survival outcomes. Results A total of 488 patients were included. Patients with high pre-chemotherapy LMR experienced significant improvements in progression-free survival (PFS, 9.2 vs. 7.6 months, P
Databáze: OpenAIRE
Externí odkaz: